Sustained expression of the estrogen receptor-α (ESR1) drives two-thirds of breast cancer and defines the ESR1-positive subtype. ESR1 engages enhancers upon estrogen stimulation to establish an oncogenic expression program 1 . Somatic copy number alterations involving the ESR1 gene occur in approximately 1% of ESR1-positive breast cancers 2-5 , suggesting that other mechanisms underlie the persistent expression of ESR1. We report significant enrichment of somatic mutations within the set of regulatory elements (SRE) regulating ESR1 in 7% of ESR1-positive breast cancers. These mutations regulate ESR1 expression by modulating transcription factor binding to the DNA. The SRE includes a recurrently mutated enhancer whose activity is also affected by rs9383590, a functional inherited single-nucleotide variant (SNV) that accounts for several breast cancer risk-associated loci. Our work highlights the importance of considering the combinatorial activity of regulatory elements as a single unit to delineate the impact of noncoding genetic alterations on single genes in cancer.
Sustained expression of the estrogen receptor-α (ESR1) drives two-thirds of breast cancer and defines the ESR1-positive subtype. ESR1 engages enhancers upon estrogen stimulation to establish an oncogenic expression program 1 . Somatic copy number alterations involving the ESR1 gene occur in approximately 1% of ESR1-positive breast cancers
, suggesting that other mechanisms underlie the persistent expression of ESR1. We report significant enrichment of somatic mutations within the set of regulatory elements (SRE) regulating ESR1 in 7% of ESR1-positive breast cancers. These mutations regulate ESR1 expression by modulating transcription factor binding to the DNA. The SRE includes a recurrently mutated enhancer whose activity is also affected by rs9383590, a functional inherited single-nucleotide variant (SNV) that accounts for several breast cancer risk-associated loci. Our work highlights the importance of considering the combinatorial activity of regulatory elements as a single unit to delineate the impact of noncoding genetic alterations on single genes in cancer.
Noncoding regulatory elements are the primary target of inherited risk variants [6] [7] [8] , and their functional relevance to cancer is supported by the mutational constraint observed within these elements across tumors 9, 10 . Functional noncoding SNVs can underlie 'single gene' diseases 11 , confirming their ability to exert large phenotypic effects commonly associated with coding variants. This is highlighted in sporadic and familial melanoma, where somatic and germline genetic alterations in the promoter of TERT (which encodes telomerase) favor oncogenesis through an increase in TERT expression 12, 13 .
Genome-wide association studies (GWAS) have identified several SNVs associated with breast cancer risk at the ESR1 locus among individuals of European and East Asian ancestry [14] [15] [16] [17] [18] . The population-specific patterns of linkage disequilibrium (LD) among the different lead SNVs seem consistent with a single underlying causal SNV. GWAS risk loci are enriched in regulatory elements, and they function by altering gene expression [6] [7] [8] . To identify the functional SNV(s), we first intersected all SNVs within a 5-Mb window of the original ESR1 locus lead SNVs with functional annotations generated by the ENCODE project 19 in MCF-7 and T-47D ESR1-positive breast cancer cells. We then calculated the population-specific LD between the European and the East Asian lead SNVs (rs3734805 and rs2046210, respectively) and the neighboring SNVs using the genotype data from the 1000 Genomes Project 20 . We identified nine SNVs common to both Europeans and East Asians that share LD with the original population-specific lead SNVs (r 2 ≥ 0.8 in both populations). SNVs rs9383590 and rs9397068, which were in perfect LD with each other and located 95 bp apart within the same DNase I hypersensitivity site (DHS), coincided with multiple functional genomic annotations generated by the ENCODE project 19 (Fig. 1a and Supplementary  Figs. 1 and 2) . These SNVs were also in strong LD (r 2 = 0.81) with the European breast cancer lead SNV rs9383938 (ref. 17) . The rs9383590 SNV mapped to the second position of a GATA DNA recognition motif (Fig. 1b) . The intragenomic replicates (IGR) tool 6 (Online Methods) predicted a decrease in the chromatin binding intensity of GATA3 for the variant allele ( Fig. 1c) , which was supported by allele-specific chromatin immunoprecipitation (ChIP)-qPCR in the heterozygous HCC1419 breast cancer cell line ( Fig. 1d) .
Enhancers regulate gene expression through physical interaction with the promoters of their target genes. Cross-cell-type correlation in DNase I hypersensitivity (C3D) 21, 22 (r ≥ 0.7; Online Methods) identified the enhancer harboring the rs9383590 SNV as potentially Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer interacting with the ESR1 promoter ( Fig. 2a) . This interaction is corroborated by RNA polymerase II (Pol II) chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) data from MCF-7 cells produced by the ENCODE project 19 (Fig. 2a) . To determine whether the rs9383590 SNV affects ESR1 gene expression, we performed an expression quantitative trait locus (eQTL) analysis. We did not observe an additive association between the variant allele of the rs9383590 SNV and ESR1 expression in ESR1-positive breast tumors profiled by the Cancer Genome Atlas (TCGA) or the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) 23 . However, a linked SNV, rs9397435 (r 2 = 0.97 and r 2 = 1 with rs9383590 in Europeans and East Asians, respectively), was previously reported as a recessive eQTL associated with ESR1 expression in breast tumor samples 18 . Consistent with those results, we observed a weak recessive eQTL among the luminal breast tumors in the larger METABRIC sample, using the rs9397437 SNV as proxy for the rs9383590 SNV (r 2 = 1 among Europeans and East Asians) (n = 970, P = 0.039) ( Fig. 2b) (Online Methods) . This eQTL should be interpreted with caution, as it was not observed within the TCGA samples. However, a luciferase reporter assay showed increased enhancer activity for the rs9383590 SNV variant allele ( Fig. 2c) . In addition, Li et al. 24 observed a significant allelic imbalance among TCGA breast tumors heterozygous for the lead East Asian SNV rs2046210. Using SNV rs9397437 as a proxy, we observed a consistent allelic imbalance in ESR1 expression among heterozygous breast tumors measured with two independent coding marker SNVs (rs2077647 and rs1801132; P < 0.05) ( Fig. 2d and Online Methods) and within the heterozygous HCC1419 breast cancer cell line (P = 1.13 × 10 −4 ) ( Supplementary Fig. 3 and Online Methods). A similar result for the rs9397437 SNV was reported by Dunning et al. 25 . The variant allele of the rs9397068 SNV also increased enhancer activity ( Supplementary Fig. 4 ). However, the effect of both SNVs did not appear to be additive ( Supplementary Fig. 4) .
Together with the reference-allele-biased binding of GATA3, these results suggests that GATA3 may act as repressor, which has been previously reported by others 26 .
Convergence of inherited risk variants and acquired somatic mutations on regulatory elements occurs at the TERT promoter in melanoma 12 . Using a set of 98 breast cancer samples profiled by whole-genome sequencing (WGS) 27 , we found two samples harboring l e t t e r s a somatic mutation in the enhancer modulated by the rs9383590 SNV ( Fig. 3a) . Because the SRE of a gene tightly regulates its expression 28 , we hypothesized that mutations within the SRE of ESR1 could account for its persistent expression in breast cancer. We first delineated the SRE of ESR1 using the C3D method. This predicted the physical interaction of 24 regulatory elements with the ESR1 promoter within a 1-Mb window of its transcription start site (r ≥ 0.7) (Supplementary Table 1 ). Eighteen of these predicted interactions were validated by first-or second-order interactions identified in the Pol II ChIA-PET data sets 19 (Supplementary Fig. 5 ). We then identified mutations in the ESR1 SRE in approximately 10% of the 98 WGS breast cancer samples (10/98). Nine of these mutations are found in seven enhancers, and one is in the ESR1 promoter ( Fig. 3b) . We validated the interaction between all mutated enhancers and the ESR1 promoter by chromatin conformation capture-based assays in MCF-7 cells ( Supplementary  Fig. 5 ). Of note, each mutated enhancer was flanked by nucleosomes containing histone H3 acetylated on Lys27 (H3K27ac) in breast cancer cells, a feature of active enhancer elements 29 (Fig. 3c) .
To determine whether the burden of mutations found in the SRE of ESR1 is significantly more than expected by chance, we designed a conservative analytical approach, termed mutational significance within the regulatory element set (MuSE) ( Fig. 3d and Online Methods). Briefly, with this approach we consider all regulatory elements, or DHSs, predicted to interact with the ESR1 promoter as a single unit, which is analogous to splicing together the exons of a gene. We then test for an excess of mutations within the ESR1 SRE using a binomial probability test given a genome-wide mutation rate (gBMR) and local background mutation rate (lBMR). The gBMR is calculated from all DHSs including the ESR1 SRE. The lBMR is calculated from the DHSs surrounding the ESR1 gene that are not connected to its promoter on the basis of C3D ( Fig. 3d) . Each type of mutation is tested separately, and the P values are combined using Fisher's method (Online Methods). This approach identified a significant enrichment of noncoding somatic mutations within the ESR1 SRE (SRE r ≥ 0.7; size = 20,744 bp; n = 10 mutations observed; P = 8.06 × 10 −3 ) ( Fig. 3b and Supplementary Table 2 ). The number of nucleotides considered exceeds what is typical of coding sequences, which hinders the statistical significance. For example, the median length of a human protein is 375 amino acids 30 , which corresponds to 1,125 nucleotides. For comparison, the SRE of ESR1 is 20,744 nucleotides. Increasing the correlation threshold used for the C3D-predicted promoter-enhancer interactions improved the significance of the measured enrichment of mutations in the ESR1 SRE, despite the inclusion of fewer mutations (r ≥ 0.9; 7,746 bp; n = 6; P = 2.57 × 10 −4 ). The statistical enrichment was also improved by restricting the analysis to ESR1-positive tumors (r ≥ 0.9; 7,746 bp; n = 5; P = 7.02 × 10 −5 ) (~7% (5/73)) (Supplementary Table 2 ). The mutational significance appeared to be specific to breast cancer mutations, as we did not detect an enrichment of somatic mutations within the ESR1 SRE defined in breast cancer cells using mutations npg l e t t e r s called in WGS of 88 liver hepatocellular carcinomas 27 (Fig. 3b) .
To determine whether the observed enrichment is greater than expected by chance, we performed a genome-wide MuSE analysis restricted to mutations called in ESR1-positive breast cancer. Focusing on all RefSeq-annotated genes with a promoter DHS in MCF-7 cells connecting to at least one regulatory element (C3D r ≥ 0.9), we found a significant enrichment of mutations in only the SRE of ESR1 (Fig. 3e ) (FDR q-value = 0.045).
To independently investigate whether the ESR1 SRE is recurrently altered in breast cancer, we sequenced the ESR1 SRE in a set of 52 primary ESR1-positive breast tumors from the IMPACT (NCT01505400) and COMPACT trials. We identified three (~6%) somatic point mutations (chr6:151955219:G>T; chr6:151979547: A>G; chr6:152075097:G>C) within enhancers interacting with the ESR1 promoter (C3D; r ≥ 0.7) ( Fig. 3f) . These mutations had a tumor fraction of 0.42, 0.32 and 0.03, respectively (Supplementary Table 3 ). The chr6:151955219:G>T falls within the enhancer altered by the rs9383590 SNV ( Fig. 3a) and is located 27 bp away from the previously characterized chr6:151955192:A>G mutation.
Similarly to inherited risk variants, noncoding somatic mutations can affect transcription factor activity 31 . All somatic mutations found in the ESR1 SRE fell within or mapped near relevant transcription factor DNA recognition motifs ( Fig. 4a and Supplementary Fig. 6 ). In addition, all mutations were predicted by IGR 6 l e t t e r s chromatin binding of known regulators of ESR1 expression, including GATA3, cohesin, SIN3A and ESR1 ( Fig. 4b and Supplementary  Fig. 7) . Ten out of eleven tested mutations significantly altered the transactivation potential of their regulatory elements ( Fig. 4c and  Supplementary Fig. 8 ). Next, we focused on the mutations within the four enhancers with the strongest predicted interaction with the ESR1 promoter (r ≥ 0.9) and the promoter itself. These elements correspond to the MuSE analysis that passed multiple testing correction (FDR < 0.05). All six mutations affecting these regulatory elements identified in ESR1-positive tumors had a significant impact on their transactivation potential (P < 0.05), including the chr6:151955219: G>T mutation from the validation set (Fig. 4c) . The chr6:151924498: T>C mutant allele decreased enhancer activity compared to the wild-type sequence, but the remaining five (83%) mutant alleles significantly increased reporter gene expression compared to the wild-type sequence (P < 0.05). We confirmed the regulatory role of these enhancers on ESR1 gene expression by deleting each of the affected enhancers using the CRISPR-Cas9 system in T-47D cells stably expressing Cas9 (Online Methods). The deletion of two of the enhancers significantly decreased ESR1 expression, and a trend was observed for the remaining enhancers (Fig. 4d) . Although the deletions are relatively large, they correspond to a small fragment of the SRE, suggesting a substantial contribution from single elements to ESR1 expression. )   TAL1  TWIST1  TAL1  CDC5L  HOXD10  NR1D1  IRF1  IRF9  IRF7  IRF3  PRDM1  STAT2  IRF2  IRF8  IRF1  IRF7  POU2F1  POU6F1  FOXQ1  HOXA10  POU6F1  POU3F2  CDX1   TAL1  TFE2  TYY1  TFE2  NDF1  TAL1  SNAl1  HTF4  MYOD1  PLAG1  PAX8  JUND  JUN  SMRC1   JUNB  PITX2  POU2F2  GFI1B  HOXB1   PLAG1  PAX8  JUND  JUN  SMARC1  FOSB  JUNB  PITX2  POU2F2  GFl1B  HOXB1  RREB1   ELK3  OTX1  THRA  THRB  MYOG  HTF4  MYOD1  TFAP4  HTF4  MYF6  THRA  ZBTB7A  SPZ1  GLl1  ERR2  KLF4  P63   DDIT3  ZBTB4  NFATC2  NFATC3  PLAG1  SOX18  PBX1  PRGR  BHE41  SNAl2  HLTF   MAFA   CTCF   HOXD9   DDIT3   SP1 l e t t e r s
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By demonstrating that the inherited risk variant and somatic point mutations that populate the SRE of ESR1 behave as gain-of-function genetic alterations, our results provide a mechanism that could explain the sustained expression of ESR1 in approximately 7% of ESR1-positive breast cancer patients. This finding contrasts with gain-of-function coding mutations that typically present as mutations recurrently targeting a single codon 34 . Hence, noncoding mutational hot spots may be rare. Instead, mutations affecting distinct regulatory elements converging on the same gene, such as those reported here, may represent the mutational pattern of noncoding driver mutations. These do not need to directly target DNA recognition motifs. Indeed, recent work has found that noncoding mutations can influence transcription factor activity despite falling outside DNA recognition motifs 35 . Taken together, our results support the idea that noncoding mutations relevant to cancer development and the genes they target can be identified by an SRE-focused approach that is inclusive of mutations outside of DNA recognition motifs. 
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Methods and any associated references are available in the online version of the paper.
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ONLINE METhODS
Genotype calling, linkage disequilibrium and multidimensional scaling. The raw genotype data of the METABRIC samples 23 were downloaded from the European Genome-phenome Archive (EGAS00000000083). The raw genotype data of the TCGA samples were downloaded from the TCGA data portal. The genotypes of the METABRIC and TCGA samples were called using Birdseed 37 . The phase 3 genotype data for the 1000 Genomes Project samples 20 were downloaded from the 1000 Genomes website. Linkage disequilibrium (LD) was calculated using VCFtools 38 within the continental European (CEU, TSI, FIN, GBR and IBS; n = 503) and East Asian (CHB, JPT, CHS, CDX and KHV; n = 504) groups. The SNVs in LD with GWAS lead SNVs are presented in Supplementary Table 4 . Ancestry was determined by merging the genotype data with the 1000 Genomes samples and performing multidimensional scaling (MDS) of the genotype data using PLINK 39 (Supplementary  Figs. 10 and 11) .
Intragenomic replicates (IGR).
The functional impact of SNVs on transcription factor binding was predicted using the IGR tool as previously described 6 . Briefly, we compare the average ChIP-seq signal intensity across genomic loci that contain short DNA sequences 7 nt in length (7-mers) that match the reference allele and its surrounding DNA sequence against the average signal intensity at genomic loci that contain 7-mers that differ only by the variant allele of each SNV. All 7-mers from a sliding window surrounding each SNV are considered. The 7-mer with the highest average intensity matching the reference allele is tested against the 7-mer with the highest average intensity that matches the variant allele. The genomic locations of all 7-mers are filtered to include only sites within open chromatin. The wgEncodeUwDnaseMcf7P-kRep1.narrowPeak and wgEncodeUwDnaseT47dPkRep1.narrowPeak called DHSs produced as part of the ENCODE project 19 were used as filters for the MCF-7 and T-47D cells, respectively. The aligned ChIP-seq files were downloaded from the ENCODE website. The complete list of files used in the analysis is available in Supplementary Table 5 . Signal files were generated using MACS 40 . All analyses were performed with hg19. eQTL analysis. We used the sample of breast tumors profiled by METABRIC 23 and TCGA. The expression data for the METABRIC samples were downloaded from the European Genome-phenome Archive. The RNA-seq data for the TCGA breast cancer samples were downloaded from the Cancer Genomics Hub.
The reads were aligned to human reference GRCh37 with Gencode version 15 human transcript annotation using STAR 41 in two-pass mode. Gene level expression values for each sample were quantified using Cufflinks 42 . The expression of ESR1 is bimodal in METABRIC and TCGA and is explained by ESR1-positive and ESR1-negative tumors (Supplementary Fig. 12) . Consistent with the METABRIC 23 analysis, we determined the expression status of TCGA tumors for ESR1, PGR and ERBB2 among TCGA samples using MClust in R. We fitted a Gaussian finite mixture model with two components. We restricted the analysis to luminal-type tumors, those that express both ESR1 and PGR, but do not overexpress ERBB2. TCGA tumor samples with low expression of ERBB2 were also identified as belonging to a separate distribution by MClust and were removed. We merged the identified luminal METABRIC discovery and validation samples and performed a quantile normalization of the merged samples using the preprocessCore library 43 in R. Statistical significance was determined using linear regression under an additive and recessive model. The reported P values are two-sided. To control for potential population stratification we included the first three components of the MDS analysis as covariates. The rs9397437 SNV was used as a proxy for the rs9383590 SNV (r 2 = 1.0 and r 2 = 1.0 among Europeans and East Asians, respectively). The gene expression values stratified by SNV genotype are presented in Supplementary Figure 13 .
Allelic imbalance. We analyzed the TCGA breast tumors profiled by RNAseq. Duplicate reads were removed using Picard. The number of aligned reads containing either the reference or variant alleles of coding marker SNVs was determined using the ABC tool 44 . The default settings of ABC were used. Marker SNVs were identified by intersecting the common SNV database (dbSNP human build 142) with refSeq exon annotations using bedTools 45 . We calculated the allelic imbalance (AI) ratio as the number of reads containing either the reference or variant allele, whichever was larger, divided by the total number of reads. We removed samples with an AI ratio greater than 0.8, as they could represent sequencing error within homozygous individuals 24 . Individuals heterozygous for the rs9397437 SNV, a proxy of the rs9383590 SNV, were compared to individuals homozygous for the common allele using an approximate Fisher-Pitman test with 10,000 permutations implemented in the coin library in R. We included markers SNVs with at least 20 samples heterozygous for the rs9397437 SNV.
Defining sets of regulatory elements (SREs). We took advantage of the known relationship between the cross-cell-type correlation in DNase I hypersensitivity signals (C3D) and chromatin interactions 21 to predict connections between regulatory elements. We used the uniformly processed DNase I hypersensitivity sequencing signal files for 79 cell lines available from the ENCODE project 19 . We performed the correlation of DNase I signal intensities in a cell type-specific manner by interrogating only DHSs identified in the MCF-7 cell line 22 . The DHSs used in our study were identified by the Hotspot algorithm 46 and produced as part of the ENCODE project 19 . We validated the predicted interactions called for breast cancer with a Pol II ChIA-PET data, profiled in MCF-7 cells, created by the ENCODE project 19 . We combined all four replicates for our analyses.
Calculating mutational significance within the regulatory element set (MuSE). DHSs predicted to interact with the gene promoter at a given correlation threshold (r ≥ 0.7-0.9) are combined to create the test region or SRE. We use the binomial test implement in R to assess whether the observed number of mutations within the test region is greater than expected given both a genomewide and local background mutation rate (lBMR and gBMR, respectively). The approach is comparable to that employed by MutSig 47 and MuSiC 48 but is applied to noncoding regions and mutations. We calculate the lBMR using the remaining DHSs that are below the correlation threshold but within the specified window surrounding the anchor DHS. This approach is thought to be conservative, as it is possible that mutations included in the lBMR are functional. It is important that the lBMR and gBMR be calculated from DHSs and that these DHSs be cell type-specific, because somatic mutations have been shown to preferentially fall in heterochromatic noncoding regions in a cell type-specific manner 9, 10 . To control for different rates of mutations, a separate binomial test is performed for each of the six mutation types (n), and a final combined P value is calculated using Fisher's method from a χ 2 distribution with 2n degrees of freedom in R. Only one mutation within the test region is counted per tumor. However, all mutations contribute to the BMR calculation, which again should be conservative. If we are unable to calculate the lBMR for a given mutation type, because we do not observe a mutation within the window, we use the gBMR for that mutation type. We excluded tumors profiled by whole-exome sequencing, because they are typically sequenced to a greater depth and regulatory elements co-occur with coding sequencings 49 .
Mutation data (discovery). The breast and liver cancer-associated mutations used in the MuSE calculations were reported by Alexandrov et al. 27 . We used the cleaned mutation data set in all analyses. We included only those samples with known ESR1 status (n = 98) in our analysis 50 . The identifiers of ESR1 positivity and triple-negative breast cancer (TNBC) tumors are listed in Supplementary Table 6 .
Targeted sequencing of the ESR1 SRE (validation). We validated the enrichment of mutations within the ESR1 SRE in an independent set of 52 primary ESR1-positive breast tumors and matched normal blood samples from the Integrated Molecular Profiling in Advanced Cancer Trial (IMPACT) and the Community Oncology Molecular Profiling in Advanced Cancer Trial (COMPACT) trials conducted at the Princess Margaret Cancer Centre (PMCC). The research ethics board of the University Health Network (UHN) approved the retrospective analysis of the breast cancer samples. Informed consent was obtained from all study participants. We used hybrid capture to isolate the ESR1 SRE elements using a custom panel of xGen Lockdown Probes (Integrated DNA Technology Inc). The 120-bp probes were spaced 60 bp apart. The probe sequences and the targeted regions are available in Supplementary  Tables 1 and 7 . Captured fragments were sequenced using 150-bp paired-end reads from a NextSeq 500 sequencer (Illumina) at the Princess
